TITLE

TREATMENT STRATEGY OF PATENT DUCTUS ARTERIOSUS IN PRETERM INFANTS

AUTHOR(S)
PISTULI, Edmond; HOXHA (QOSJA), Alketa; BAKALLI, Ilirjana; BUBA, Sokol
PUB. DATE
October 2013
SOURCE
Pedijatrija Danas: Pediatrics Today;Oct2013, Vol. 9 Issue 2, p174
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective -- This study was to assess the efficacy and safety of oral ibu-profen and intravenous ibuprofen for the early pharmacological treatment of patent ductus arteriosus (PDA) in preterm infants. Methods -- A randomized, single-blinded, controlled study was performed on premature neonates at the neonatal unit tertiary care hospital, from January 2010 to December 2012. The study enrolled 80 preterm infants with gestational age between 28-32 weeks, birth weight < 2000 g, postnatal age 48-96 h, and with echocardiographically confirmed significant PDA (a duct size >1.5 mm). The preterm infants received either intravenous or oral ibuprofen randomly as an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h after the first dose (the first treatment course). Serum creatinine (sCr), blood urea nitrogen (BUN) and urine output (UO) were recorded prior to treatment, before each dose and after the first treatment course. Results -- Forty patients were treated with oral ibuprofen and 40 with intravenous ibuprofen in this period. There was no difference between treatment groups in demographics or baseline renal function. After the first course of the treatment, the PDA closed in 28 (70%) of the patients assigned to the oral ibuprofen group, versus 23 (57.5%) of those enrolled in the intravenous ibuprofen group (p=0.35). In the evaluation of renal tolerance, none of the patients had oliguria. Moreover, in patients who underwent a second course of intravenous therapy, the urinary output significantly decreased, but the sCr levels after the first and after the second treatment course did not differ significantly from the baseline for each group. 7.5% of the intravenous group underwent surgery, versus 0% of the oral group. (p=0.23) Conclusions -- Successful pharmacological closure of PDA can be achieved by the use of ibuprofen orally or intravenously, without statistically significant difference in efficacy and safety between the two treatments. Patients treated with ibuprofen intravenously probably have a much higher risk of undergoing surgery.
ACCESSION #
91985159

 

Related Articles

  • Comparison of oral ibuprofen and intravenous indomethacin for the treatment of patent ductus arteriosus in extremely low birth weight infants. Eun Mi Yanga; Eun Song Song; Young Youn Choi // Jornal de Pediatria;Jan/Feb2013, Vol. 89 Issue 1, p33 

    Objective: There are few published reports concerning the efficacy of oral ibuprofen for the treatment of patent ductus arteriosus (PDA) in extremely low birth weight (ELBW) infants. Oral ibuprofen was compared to intravenous indomethacin regarding efficacy and safety in the treatment of PDA in...

  • Comparison of Oral Ibuprofen with Oral Indomethacin for PDA Closure in Indian Preterm Neonates: A Randomized Controlled Trial. Yadav, Sanju; Agarwal, Sheetal; Maria, Arti; Dudeja, Ajay; Dubey, N.; Anand, Puneet; Yadav, Dinesh // Pediatric Cardiology;Jun2014, Vol. 35 Issue 5, p824 

    Oral ibuprofen is being used as an alternative to indomethacin in medical management of patent ductus arteriosus (PDA), but limited data exist on oral efficacy of these drugs for PDA closure in India. To assess and compare the efficacy of oral ibuprofen and oral indomethacin for PDA closure in...

  • Para Cierre del Ductus Arterioso Permeable con Ibuprofeno por Vía Enteral. Servicio de Neonatología Hospital Infantil del Estado de Sonora. Rojas-Villalvazo, José Manuel; Ramírez-Rodríguez, Carlos Arturo; Sosa-Cruz, Erika Flor; Corella-Valencia, Jaime // Boletin Clinico Hospital Infantil del Estado de Sonora;Sep2013, Vol. 30 Issue 2, p76 

    Introduction: Patent ductusarteriosus (PDA) is the most common cardiocirculatory defects in preterm infants . It has an incidence of 80% in less than 1,000 g and / or 28 weeks gestation. A hemodynamically significant patent ductusarteriosus (PDA-HS) is symptomatic and evidenced by echocardiogram...

  • Ibuprofen and acute kidney injury in the newborn. Fanos, Vassilios; Antonucci, Roberto; Zaffanello, Marco // Turkish Journal of Pediatrics;May/Jun2010, Vol. 52 Issue 3, p231 

    The pharmacological treatment of patent ductus arteriosus (PDA) in preterm infants remains a controversial issue, particularly with regard to the type of drug to be prescribed (ibuprofen or indomethacin) and the timing of the treatment, given their comparable effectiveness. For many years,...

  • Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants. De Carolis, Maria Pia; Romagnoli, Constantino; Polimeni, Valentina; Piersigilli, Fiammetta; Zecca, Enrico; Papacci, Patrizia; Delogu, Angelica Bibiana; Tortorolo, Giuseppe // European Journal of Pediatrics;2000, Vol. 159 Issue 5, p364 

    Abstract This study was aimed at evaluating the efficacy of ibuprofen in the prophylaxis of patent ductus arteriosus (PDA) in very preterm neonates and at detecting eventual side-effects. A total of 46 preterm neonates with gestational age under 31 weeks were randomly assigned at 2 h of life: 23...

  • Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants. Amitai, Yona; Hammerman, Cathy // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Jan2012, Vol. 97 Issue 1, pF76 

    A letter to the editor is presented in response to the article by Barzilay et al on the efficacy of ibuprofen for patent ductus arteriosus (PDA) closure.

  • Differential renal adverse effects of ibuprofen and indomethacin in preterm infants: a review. Pacifici, Gian Maria // Clinical Pharmacology;2014, Vol. 6, p111 

    Objective: The objective of this study was to evaluate the extent of renal adverse effects caused by ibuprofen or indomethacin in order to choose the safer drug to administer to preterm infants. Methods: The following three parameters of renal function were taken into consideration: 1) the urine...

  • Treatment of patent ductus arteriosus: indomethacin or ibuprofen? Sekar, K. C.; Corff, K. E. // Journal of Perinatology;May2008 Supplement, Vol. 28, pS60 

    Persistent patent ductus arteriosus (PDA) in preterm infants can result in serious hemodynamic changes causing respiratory, gastrointestinal and renal morbidities if not treated within the first week of life. The treatment options available are a conservative approach, pharmacological treatment...

  • Ibuprofen Lysine Injection. Cada, Dennis J.; Levien, Terri; Baker, Danial E. // Hospital Pharmacy;Oct2006, Vol. 41 Issue 10, p970 

    The article provides information on the drug ibuprofen lysine injection. It is being used as cardiovascular agent and agents for patent ductus arteriosus (PDA). It is said that the drug is comparable to indomethacin. A background on the clinical trial that was conducted to prove the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics